Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
Clinical trial NCT02296242 · COMPLETED
Trial details
- NCT number
- NCT02296242
- Sponsor
- BioMed Valley Discoveries, Inc
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-01
- Primary completion
- 2017-06-15
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.